Amphotericin B Liposome For Injection Use In Pregnancy & Lactation

Fertility: Teratogenicity studies in both rats and rabbits reported that Amphotericin B Liposome for Injection has no teratogenic potential in these species.
Pregnancy: The safety of Amphotericin B Liposome for Injection in pregnant women has not been reported. Amphotericin B Liposome for Injection should only be used during pregnancy if the possible benefits to be derived outweigh the potential risks to the mother and foetus. Systemic fungal infections have been successfully treated in pregnant women with conventional amphotericin B without obvious effect on the foetus, but the number of cases reported is insufficient to draw any conclusions on the safety of Amphotericin B Liposome for Injection in pregnancy.
Lactation: It is unknown whether Amphotericin B Liposome for Injection is excreted in human breast milk. A decision on whether to breastfeed while receiving Amphotericin B Liposome for Injection should take into account the potential risk to the child as well as the benefit of breastfeeding for the child and the benefit of Amphotericin B Liposome for Injection therapy for the mother.